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How BMP-2 induces EMT and breast cancer
stemness through Rb and CD44?
Guanglin Zhang1, Peide Huang1,2, Anan Chen3, Weiyi He1, Zhen Li1, Ge Liu1 and Ju Wang1
Tumor cells, originating from rare stem cells respon-
sible for maintaining tumors, are organized hierarchically
in certain malignancies1. Breast cancer stem cells (BCSCs,
CD44+/CD24−) promote tumor progression and exhibit
enhanced invasive properties that favor distant metastasis
in patients with breast cancer2, 3.
In our previous study, we showed that bone morpho-
genetic protein (BMP)-2 inhibited cancer cell growth
in vitro and in vivo by inducing G1 arrest and apoptosis in
MDA-MB-231 and MCF-7 human breast cancer cell
lines4. BMPs are known to be involved in metastatic
progression and tumorigenesis of many types of cancer5,
but functional studies have revealed contradictory roles of
BMPs in both cancer promotion and inhibition6. Conse-
quently, in our recent publication, we investigated the
mechanism underlying the effect of BMP-2 on breast
cancer metastasis using a comprehensive molecular
approach in breast cancer cell lines and clinical breast
cancer samples7.
We observed that rhBMP-2 induced epithelial–-
mesenchymal transition (EMT) in three breast cancer cell
lines (MCF-7, MDA-MB-231, and a mouse breast cancer
cell line 4T1) and enhanced the migratory and invasive
capabilities of these cells both in vitro and in vivo. Next,
we used the RT²Proﬁler PCR array (Qiagen, Hilden,
Germany) to detect changes in the expression of 84 genes
known to be associated with tumor metastasis. The most
upregulated genes were CD44 and MMP11, while the
most downregulated genes were RB1 and CDH1 (E-
cadherin)7.
CD44, an alternatively spliced transmembrane protein,
functions as a receptor for hyaluronan and a. co-receptor
for multiple receptor kinases associated with breast can-
cer8. CD44 expression is essential for maintaining the
cancer stem cell phenotype9. Immunocytochemistry
assays showed that rhBMP-2 upregulated CD44 expres-
sion and induced the redistribution of cellular CD44 to
the leading edges and lamellipodia of MCF-7 cells. Using
Smad4–siRNA silencing and the CD44 promoter-
luciferase reporter system, we further showed that
rhBMP-2 upregulated CD44 expression in MCF-7 cells
via the conventional Smad-dependent signaling pathway.
Binding of Smad4 to the SBE (Smad-binding element)-
rich region of the CD44 promoter activated CD44
expression. BMP-2 also promoted the formation of tumor
spheroids and increased the population of CD44+/CD24−
cells in MCF-7 breast cancer cells. These observations
suggest that rhBMP-2 enhances the stemness of breast
cancer cells.
Rb (retinoblastoma) is a well-known tumor suppressor
that initiates and maintains cell cycle arrest and mod-
ulates apoptosis. Functional loss of the RB contributes to
aggressive tumor phenotype and induces EMT in breast
cancer10. Unlike the Rb Ser567 phosphorylation-mediated
and p-38 signaling pathway-activated induction of
ubiquitin-dependent degradation of Rb in melanoma
cells11, we observed that Rb was phosphorylated on
Ser807/811 and subjected to ubiquitin-dependent degra-
dation through a Smad-independent PI3K/AKT signaling
pathway in BMP-2-activated breast cancer cells. Thus, we
identiﬁed a unique mechanism of rhBMP-2 -mediated Rb
downregulation that promotes metastasis in MCF-7 cells.
Our results further showed that Rb reduction and
activation of the PI3K/Akt pathway contributed partially
to CD44 upregulation. CD44 expression was signiﬁcantly
upregulated in Rb-silenced cells than in control MCF-7
© The Author(s). 2018
OpenAccessThis article is licensedunder aCreativeCommonsAttribution 4.0 International License,whichpermits use, sharing, adaptation, distribution and reproduction
in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if
changesweremade. The images or other third partymaterial in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to thematerial. If
material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Correspondence: Ju Wang (wangju1688@163.com)
1Institute of Biomedicine, Guangdong Provincial Key Laboratory of
Bioengineering Medicine, National Engineering Research Centre of Genetic
Medicine, College of Life Science and Technology, Jinan University,
Guangzhou 510632, China
2Section for Molecular Disease Biology, Department of Drug Design and
Pharmacology, Faculty of Health and Medical Sciences, University of
Copenhagen, 2200 Copenhagen N, Denmark
Full list of author information is available at the end of the article
Guanglin Zhang, Peide Huang, and Anan Chen contributed equally to this work.
Ofﬁcial journal of the Cell Death Differentiation Association
cells. rhBMP-2-mediated CD44 upregulation was
impaired in cells pretreated with PI3K and AKT inhibitors
(LY294002 and MK-2206)7. These results were consistent
with those of a recent study, which showed that CD44
expression was required for collective motility and
metastatic progression initiated by loss of Rb function in
breast cancer12. Our study also suggested that cross-talks
between the Rb and CD44 pathways were required for
BMP-2-dependent EMT and development of BCSCs.
Overall, this is the ﬁrst study demonstrating that BMP-2
is a driving factor for promoting EMT and breast cancer
stemness via Rb and CD44 signaling pathways (Fig. 1).
Finally, we suggest that both PI3K/AKT and Smad sig-
naling are involved in the rhBMP-2-mediated regulation
of RB and CD44 expression. Our in vitro and in vivo
ﬁndings highlight the crucial roles of BMP-2, Rb, and
CD44 in breast cancer metastasis, which may provide new
strategies for determining the prognosis and treatment of
advanced breast cancer.
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